Identifying pain characteristics to improve pain medication effectiveness
Official title: Sensory Phenotyping to Enhance Neuropathic Pain Drug Development
Funded at Beth Israel Deaconess Medical Center · NIH-10724809 · Data updated 2026-11-12
This study is looking at how each person's experience of pain can help doctors find the best pain relief options for them, so if you have neuropathic pain, you might get treatments that work better just for you!
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,600,475 |
| NIH project number | 1UG3NS130592-01A1 |
| Project ID | NIH-10724809 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from neuropathic pain who have not found relief with standard pain medications.
✕Less likely to help
Patients with acute pain conditions or those who do not have neuropathic pain may not benefit from this research.
What this research studies
This research focuses on understanding how individual differences in pain perception can help tailor pain treatments for better outcomes. By using a technique called quantitative sensory testing, researchers aim to identify specific sensory profiles that can predict how well patients will respond to different pain medications. The goal is to develop a more personalized approach to pain management, moving away from a one-size-fits-all strategy. This could lead to more effective treatments for those suffering from neuropathic pain.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of pain medications for patients with neuropathic pain.
How similar studies have gone: Preliminary evidence suggests that identifying pain phenotypes can predict treatment outcomes, indicating potential success for this approach.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Freeman, Roy — Beth Israel Deaconess Medical Center
- Study coordinator: Freeman, Roy
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Parmodulins with Low Abuse Potential for Neuropathic Pain
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.